Bernhard W N, Schalick L M, Delaney P A, Bernhard T M, Barnas G M
Division of Anesthesiology, Shock Trauma Center, University of Maryland Medical Systems, Baltimore, USA.
Aviat Space Environ Med. 1998 Sep;69(9):883-6.
In a double-blind study, we compared the efficacy of a combination of sustained-release acetazolamide and low-dose dexamethasone and acetazolamide alone for prophylaxis against acute mountain sickness (AMS) caused by rapid ascent to high altitude. Before ascent, 13 subjects were randomly assigned to receive a combination of one sustained-release acetazolamide capsule (500 mg) in the afternoon and 4 mg dexamethasone every 12 h, or a combination of the same dose of acetazolamide once daily and a placebo every 12 h. Days 1 and 2 were spent at 3698 m (La Paz, Bolivia), while days 3 and 4 were spent at 5334 m (Mount Chaclataya, Bolivia). Ascent was by 2 h motor vehicle ride. Heart rates, peripheral oxygen saturations and a modified score derived from the Environmental Symptom Questionnaire (modified-ESQ) were measured on each day. In addition, weighted averages of the cerebral (AMS-C) and respiratory (AMS-R) symptoms were calculated for days 3 and 4.
Heart rate and modified-ESQ scores increased on days 3 and 4 compared with the other days in the acetazolamide/placebo group only (p < 0.05). Oxygen saturations decreased in both groups on days 3 and 4 (p < 0.05), but the decrease was greater in the acetazolamide/placebo group (p < 0.05). AMS-C and AMS-R scores rose above the suggested thresholds for indication of AMS on days 3 and 4 in the acetazolamide/placebo group only (p < 0.05).
We conclude that this combination of sustained-release acetazolamide once daily and low-dose dexamethasone twice daily is more effective in ameliorating the symptoms of AMS than azetazolamide alone at the ascent that was studied.
在一项双盲研究中,我们比较了缓释乙酰唑胺与低剂量地塞米松联合用药和单独使用乙酰唑胺预防因快速登高至高原引起的急性高原病(AMS)的疗效。登高前,13名受试者被随机分配,一组在下午服用一粒缓释乙酰唑胺胶囊(500毫克)并每12小时服用4毫克地塞米松,另一组每天服用相同剂量的乙酰唑胺一次并每12小时服用一次安慰剂。第1天和第2天在海拔3698米处(玻利维亚拉巴斯)度过,而第3天和第4天在海拔5334米处(玻利维亚查克拉塔亚山)度过。通过乘坐2小时的机动车登高。每天测量心率、外周血氧饱和度以及根据环境症状问卷得出的修正评分(修正-ESQ)。此外,计算了第3天和第4天大脑(AMS-C)和呼吸(AMS-R)症状的加权平均值。
仅在乙酰唑胺/安慰剂组中,第3天和第4天的心率和修正-ESQ评分与其他天数相比有所增加(p<0.05)。两组在第3天和第4天的血氧饱和度均下降(p<0.05),但乙酰唑胺/安慰剂组下降幅度更大(p<0.05)。仅在乙酰唑胺/安慰剂组中,第3天和第4天的AMS-C和AMS-R评分高于提示AMS的阈值(p<0.05)。
我们得出结论,在本研究的登高过程中,每日一次的缓释乙酰唑胺与每日两次的低剂量地塞米松联合用药在改善AMS症状方面比单独使用乙酰唑胺更有效。